Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Part 1: A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Severe COVID-19 Pneumonia Part 2: A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)

NCT04345614 is registered in ClinicalTrials.gov with CalciMedica, Inc. as lead sponsor.

NCT NCT04345614
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04345614 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Part 1: A Randomized Controlled Open-Label Study of CM4620 Injectable Emulsion (CM4620-IE) in Patients With Severe COVID-19 Pneumonia Part 2: A Randomized Double Blind, Placebo-Controlled Study of Auxora for the Treatment of Severe COVID-19 Pneumonia (CARDEA)
Lead sponsor
CalciMedica, Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 8, 2020
Completion date
July 30, 2021
Enrollment
314 (actual)
Sites
17

Conditions

As the registry lists them; a condition with its own page is linked.

pneumonia